STUDIES ON THE DIFFERENT METABOLIC PATHWAYS OF ANTIPYRINE IN RATS - INFLUENCE OF PHENOBARBITAL AND 3-METHYLCHOLANTHRENE TREATMENT

被引:159
作者
DANHOF, M
KROM, DP
BREIMER, DD
机构
[1] Department of Pharmacology, Subfaculty of Pharmacy, Sylvius Laboratories., 2300, RA, Leiden
关键词
D O I
10.3109/00498257909042337
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. The amounts of antipyrine and its metabolites excreted in 24 h urine after i.v. injection of 10 mg antipyrine into male Wistar rats were quantified after enzymic hydrolysis with glucuronidase/aryl sulphatase. in 24h 2.7% of the administered dose was excreted as unchanged antipyrine, 13.3% as 4-hydroxyantipyrine, 7.4% as norantipyrine, 28.9% as 3-hydroxymethylantipyrine and 1.1% as 3-carboxyantipyrine. 2. Treatment with phenobarbital decreased the antipyrine half-life from 65 to 30 min, but did not significantly change the urinary metabolite profile. Only the amount of 3-carboxyantipyrine was significantly different and increased from 1.1 to 2.6% dose. 3. 3-Methylcholanthrene treatment resulted in a decrease of antipyrine half-life from 72 to 34 min. After treatment 4-hydroxyantipyrine was increased from 13.4% to 25.6% dose, whereas 3-hydroxymethylantipyrine was decreased from 26.8% to 8.5% and 3-carboxyantipyrine from 1.3% to 0.2% of the dose respectively; norantipyrine was unchanged. 4. It is concluded that different types of hepatic cytochrome P-450 may be involved in the formation of 4-hydroxyantipyrine on one hand and the formation of 3-hydroxymethylantipyrine on the other. Another possibility is that in methylcholanthrene-treated animals another haemoprotein is formed that results in the formation of more 4-hydroxyantipyrine and less 3-hydroxymethylantipyrine. In any case, the urinary metabolite profile of antipyrine can be used to study changes in the activity of different cytochromes in drug metabolism studies. © 1979 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.
引用
收藏
页码:695 / 702
页数:8
相关论文
共 31 条
[1]   IMPAIRED OXIDATION OF ANTIPYRINE IN STAGNANT LOOP RATS [J].
AARBAKKE, J .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1977, 12 (08) :929-935
[2]  
AARBAKKE J, 1978, ACTA PHARMACOL TOX, V43, P64
[3]   NORPHENAZONE, A NEW METABOLITE OF PHENAZONE IN HUMAN URINE [J].
BATY, JD ;
PRICEEVA.DA .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1973, 25 (01) :83-84
[4]   INFLUENCE OF PHENOBARBITAL ON DISPOSITION OF CLONAZEPAM AND ANTIPYRINE IN DOG [J].
BEKERSKY, I ;
MAGGIO, AC ;
MATTALIANO, V ;
BOXENBAUM, HG ;
MAYNARD, DE ;
COHN, PD ;
KAPLAN, SA .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1977, 5 (05) :507-512
[5]   INCREASED CLEARANCE OF ANTIPYRINE AND D-PROPRANOLOL AFTER PHENOBARBITAL TREATMENT IN MONKEY - RELATIVE CONTRIBUTIONS OF ENZYME-INDUCTION AND INCREASED HEPATIC BLOOD-FLOW [J].
BRANCH, RA ;
SHAND, DG ;
WILKINSON, GR ;
NIES, AS .
JOURNAL OF CLINICAL INVESTIGATION, 1974, 53 (04) :1101-1107
[6]  
BRODIE BB, 1950, J PHARMAC EXP THER, V98, P976
[7]   HIGH-SPEED LIQUID-CHROMATOGRAPHY, RADIOASSAY-C-14 AND SPECTROPHOTOMETRY FOR MEASURING ANTIPYRINE PLASMA HALF-LIFE IN RHESUS-MONKEYS (MACACA-MULATTA) [J].
CLARK, CR ;
KRIEGER, RI ;
MILLER, JL .
PHARMACOLOGY, 1978, 17 (02) :98-103
[8]   ASSAY OF ANTIPYRINE AND ITS PRIMARY METABOLITES IN PLASMA, SALIVA AND URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY AND SOME PRELIMINARY-RESULTS IN MAN [J].
DANHOF, M ;
GROOTVANDERVIS, ED ;
BREIMER, DD .
PHARMACOLOGY, 1979, 18 (04) :210-223
[9]  
DANHOF M, BRIT J CLIN PHARMAC
[10]  
DANHOF M, PHARMACOLOGY